Protocol Ledger

NCT06169215 · Phase II · ACTIVE NOT RECRUITING

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Interventional Phase II clinical trial protocol NCT06169215 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-23 Enrollment: 58 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06169215
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06169215
Protocol FieldVerified Registry Value
NCT IdentifierNCT06169215
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment58 participants (ACTUAL)
Registered Start Date2024-07-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI